Ananda Developments Plc - Result of General Meeting PR Newswire

21 September 2018


(“Ananda” or the “Company”)

Result of General Meeting

The Company is pleased to announce that at the General Meeting held earlier today, the resolution put to shareholders was duly passed.

As a result, the Company has completed its purchase of 15 per cent. of Liberty Herbal Technologies Limited (“LHT”), the 100% owner and developer of hapac®, a patent pending technology for vaping medicinal cannabis.

Melissa Sturgess, Executive Director of Ananda, commented: “We are very excited about the potential of hapac® and look forward to the formal launch of their product in Italy in November, following successful test marketing during 2017.”

The directors of the Company accept responsibility for the contents of this announcement.


Ananda Developments plc          +44 (0)739 269 6517

Executive Director
Melissa Sturgess

Investor Relations
Jeremy Sturgess-Smith

Peterhouse Capital Limited       +44 (0)20 7469 0930

Corporate Finance
Fungai Ndoro
Mark Anwyl

Corporate Broker
Lucy Williams
Duncan Vasey

Celicourt Communications         +44 (0)20 7520 9261
Mark Atelme
Joanna Boon

Notes to editors

About Ananda Developments PLC

Ananda Developments has been established as a company to invest in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the USA, as well as other countries around the world, changing their laws to allow for products containing constituents of Medical Cannabis to be developed, approved and sold.

A copy of the Company’s Admission Document is available at and at

Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.